key: cord-0901041-ypxx1q5t
authors: Gallichotte, Emily N.; Nehring, Mary; Young, Michael C.; Pugh, Sierra; Sexton, Nicole R.; Fitzmeyer, Emily; Quicke, Kendra M.; Richardson, Megan; Pabilonia, Kristy L.; Ehrhart, Nicole; Fosdick, Bailey K.; VandeWoude, Sue; Ebel, Gregory D.
title: Durable antibody responses in staff at two long-term care facilities, during and post SARS-CoV-2 outbreaks
date: 2021-05-05
journal: bioRxiv
DOI: 10.1101/2021.05.04.442699
sha: 833c4048155ceb318b322b7dc3973c9633e56433
doc_id: 901041
cord_uid: ypxx1q5t

SARS-CoV-2 has had a disproportionate impact on non-hospital healthcare settings such as long-term care facilities (LTCFs). The communal nature of these facilities, paired with the high-risk profile of residents, has resulted in thousands of infections and deaths and a high case fatality rate. To detect pre-symptomatic infections and identify infected workers, we performed weekly surveillance testing of staff at two LTCFs which revealed a large outbreak at one of the sites. We collected serum from staff members throughout the study and evaluated it for binding and neutralization to measure seroprevalence, seroconversion, and type and functionality of antibodies. At the site with very few incident infections, we detected that over 40% of the staff had preexisting SARS-CoV-2 neutralizing antibodies, suggesting prior exposure. At the outbreak site, we saw rapid seroconversion following infection. Neutralizing antibody levels were stable for many weeks following infection, suggesting a durable, long-lived response. Receptor-binding domain antibodies and neutralizing antibodies were strongly correlated. The site with high seroprevalence among staff had two unique introductions of SARS-CoV-2 into the facility through seronegative infected staff during the period of study but these did not result in workplace spread or outbreaks. Together our results reveal that high seroprevalence rate among staff can contribute to herd immunity within a workplace and protect against subsequent infection and spread within a facility.

tubes (catalog #368660). Samples were incubated for 30-60 minutes at room temperature to ensure clot 84 formation, spun at 1300xg for 10 minutes at 25°C with gradual acceleration and deceleration, sera were 85 aliquoted and stored at -20°C. Prior to use, sera were heat inactivated at 56°C for 30 minutes, then 86 stored at 4°C. 

The cutoffs for classifying ELISA results as positive/negative were based on the average optical density 98 (OD) values across two replicates. For each binding assay, the OD cutoff was specified as that which 99 maximizes concordance with the SARS-CoV-2 neutralization assay results, specifically that maximizing 100 the sum of the percent positive agreement (PPA) and the percent negative agreement (PNA), akin to SARS-CoV-2 whole genome sequencing. Sequencing was performed as previously described [11] .

Briefly, cDNA was generated using SuperScript IV, PCR amplification was performed with ARTIC tiled 110 primers and Q5 High-Fidelity polymerase. PCR products were purified, libraries were prepared using 111 KAPA HyperPrep Kit and unique index primers. Libraries were sequenced on the Illumina MiSeq V2 112 using 2 x 250 paired-end reads. Sequencing data were processed, quality checked, and consensus 113 sequences determined.

SARS-CoV-2 surveillance testing. We performed nasal surveillance testing for SARS-CoV-2 viral RNA 117 of staff at two long-term care facilities over a 4-6 month period (Site A, July-Oct 2020, Site B, June-Dec, 118 2020, Fig. 1 ). Samples were collected at the workplace. Site A previously experienced a large outbreak 119 in June immediately before our surveillance testing began, with 26 staff and 47 residents testing positive, 120 whereas at Site B no symptomatic or asymptomatic cases had been diagnosed prior to our surveillance 121 testing. Staff were tested at least once per week, approximately 180 unique individuals at each site 122 participated in testing, with an average of 100 staff at site A and 85 staff at site B testing weekly ( Fig.   123   1a) . Positive tests and percent positivity varied by facility, with site A only experiencing two positive tests 124 (from two different staff members) throughout their entire 17-week testing period (Fig. 1b & c) . Site B 125 experienced a large outbreak with over 15% of staff testing positive at its peak, and 24 unique staff 126 testing positive throughout the 18-week study (Fig. 1b & c) . We collected serum samples from staff at 127 both sites every 3-5 weeks, spanning the 5-month surveillance period, including a timepoint immediately 128 prior to and immediately following an outbreak in early September at site B (Fig. 1c) .

antibody binding levels gradually declined over the first 8 weeks, suggesting recent infection and 136 progression from an acute to convalescent stage (Fig. 2b) . At site B, binding levels quickly increased 137 immediately following the outbreak and were stable over the following weeks (Fig. 2b) .

SARS-CoV-2 serum neutralization. Sera were next evaluated for their ability to neutralize live SARS-139 CoV-2 virus using a standard plaque reduction neutralization test, and their 50% neutralization titers 140 were calculated (Fig. 3) . In agreement with antibody binding results, site A had 40-50% neutralizing 141 seropositivity which was maintained throughout the study, whereas at site B, rapidly increased from 10% 142 to 35% between the first sample and subsequent weeks (Fig. 3a) . At site A, neutralizing titers were 143 highly stable over the 17-week study, whereas at site B, neutralizing titers rose as individuals became 144 infected, decreased following the acute response, and were stable during convalescence (Fig. 3b) .

Neutralizing antibody levels of individuals at site B that were infected prior to the beginning of the study 146 where highly stable over the 18-week study, suggesting they were infected weeks/months prior (Fig. 3b) .

Relationship between SARS-CoV-2 polyclonal antibody binding and neutralization. To better 148 understand the relationship between binding and functionally neutralizing antibodies, spike and RBD 149 binding levels and neutralizing titers were compared (Fig. 4) . At both sites, spike and RBD levels were and neutralization (Fig. 5) . Spike binding antibody levels were high within 30 days of positive PCR test 159 and remained high throughout the monitoring period (Fig. 5a) . RBD binding levels were more variable 160 and dynamic with some individuals generating RBD-specific antibodies within 10 days following infection, 161 whereas one individual took over 60 days to seroconvert (Fig. 5b) . Neutralizing antibody titers were also 162 variable and dynamic across individuals, though most individuals generated high levels within a month 163 following infection (Fig. 5c) . In 85% of individuals, RBD-binding and neutralizing antibody levels 164 decreased during the first 2-3 months following infection then stabilized (Fig. 5b & c, dashed lines) .

When comparing the relationship between binding and neutralizing antibodies stratified by timing post-166 infection, we again saw RBD and neutralizing antibody levels generally decrease ~30 days post-167 infection, whereas spike antibodies were highly stable (Fig. 5d) . Additionally, binding and neutralizing 168 antibodies were highly correlated regardless of timing post-infection (p<0.0005).

Phylogenetic analyses reveal lack of workplace SARS-CoV-2 spread. While site A did not 170 experience any outbreaks during our surveillance testing, two individual staff members tested positive 171 during the course of our study (Fig. 1b) . These infections did not result in outbreaks or spread to other 172 staff ( Fig. 2a & 3a) . The two individuals that tested positive for SARS-CoV-2 vRNA (two weeks apart on To determine if the two viruses were genetically related, and therefore likely acquired from one 176 another, viral genomes from the cases were sequenced. Both viruses contained shared single nucleotide 177 polymorphisms (SNPs) relative to a reference strain (WA01), however they also contained 13 unique 178 SNPs that strongly distinguish one from the other (Fig. 6c) , suggesting two independent infections. 

Covid-19 -Implications for the Health 277 Care System

COVID-19 and healthcare systems: What should we do next? Public

Development of Herd Immunity to COVID-19 in Louisiana Nursing Homes

Serology testing demonstrates that antibodies 480 to SARS-CoV-2 S1-RBD correlate with neutralization of virus infection of Vero E6 cells

Analytical and clinical 484 performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers

The receptor binding domain of the viral spike protein is an 490 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus 494 neutralizing antibodies and symptomatic severity in a German COVID-19 cohort

A neutralizing human antibody binds to the N-terminal domain of the Spike 508 protein of SARS-CoV-2. Science

Potent neutralizing antibodies from COVID-19 patients define multiple targets of 515 vulnerability

Correlates of protection from SARS-CoV-2 infection

Immune correlates of SARS-CoV-2 protection

Potential SARS-CoV-2 Immune Correlates of Protection in 521 Infection and Vaccine Immunization. Pathogens

The Advisory Committee on Immunization Practices' 535

Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine -United States

Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents 540 of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks -Connecticut

Short-term impact of nursing home SARS-CoV-2 544 vaccinations on new infections, hospitalizations, and deaths

SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home 547 residents with asymptomatic COVID-19